Lifecore Q3 Revenue Falls 18.6% to $25.3M; $40.1M Net Loss Driven by Non-Cash Derivative Mark
LFCR sits 76% above its 52-week low of $3.625.
Summary
Lifecore's Q3 revenue fell 18.6% to $25.3 million and the net loss widened to $40.1 million, but $31.3 million of that loss is a non-cash derivative remeasurement; Adjusted EBITDA rose to $4.0 million. Results land as the $6.28-per-share Webster Equity Partners merger goes to a stockholder vote.
Key Events · Earnings and Guidance · LFCR
-
Q3 Revenue Down 18.6%
Total revenues were $25.3 million versus $31.1 million a year earlier; CDMO revenue fell 18% to $17.8 million and HA manufacturing fell 19% to $7.5 million. Nine-month revenue was $82.7 million, down 21.8%.
-
Net Loss Is Mostly Non-Cash
The $40.1 million Q3 net loss ($1.08 per diluted share) includes a $31.3 million non-cash change in fair value of the related-party debt derivative liability — a mark-to-market entry, not a cash outflow and not new dilution. Adjusted EBITDA rose to $4.0 million from $3.1 million.
-
Cash Generation and Liquidity
Nine-month operating cash flow was $9.5 million and free cash flow $6.9 million. The quarter ended with roughly $38.0 million of liquidity: $23.0 million of cash plus $15.0 million of revolver availability.
-
New Business Wins for 2027
Two technology transfer projects were signed in Q3 (one supporting PPQ batches for a biotech NDA, one for a large pharma's marketed product), plus three early-Q4 development programs including a Phase 2 product with a top-20 global pharma. Management expects revenue contribution beginning in 2027.
Analysis · LFCR · Life Sciences
Revenue kept shrinking — total revenues fell 18.6% to $25.3 million and CDMO revenue dropped 18% — but the headline $40.1 million net loss is mostly accounting, not cash: it includes a $31.3 million non-cash change in the fair value of the related-party debt derivative liability, a mark-to-market entry that moves with the share price and involves no cash outflow and no new shares. Strip that out and Adjusted EBITDA actually improved to $4.0 million from $3.1 million, and the company generated $9.5 million of operating cash flow over nine months. The real constraint remains the balance sheet: $38.0 million of liquidity against a $50.2 million preferred stock redemption obligation previously disclosed as due December 28, 2026. All of this is backdrop to the pending $6.28-per-share cash merger with Webster Equity Partners, which stockholders vote on at the special meeting whose record date was today, November 4, 2026 — the deal price, not the quarterly print, is what sets the stock's value.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LFCR was trading at $6.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $243.4M. The 52-week trading range was $3.63 to $8.98. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.